BioCryst Pharma (BCRX) Reports In-Line Q1 EPS

BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $9.4 million versus the consensus estimate of $5.26 million.

“We have completed enrollment in Part 1 and 2 of the APeX-1 Phase 2 clinical trial of BCX7353 for prevention of angioedema attacks and will report top-line data in the second quarter of 2017 as planned,” said Jon P. Stonehouse, President & Chief Executive Officer. “Enrollment in Part 3 has begun, and at the current enrollment pace, we expect to report complete APeX-1 results in the third quarter of 2017.”

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen